US
CA
NZ
UK
AU
IND
Last update at 2025-05-22T17:01:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy
Fri 07 Mar 25, 04:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -0.30366M | 1.04M | 1.26M | -0.27570M | 0.06M |
| Minority interest | - | - | - | - | - |
| Net income | -0.35597M | 0.75M | 1.09M | -0.24647M | 0.03M |
| Selling general administrative | 1.73M | 1.20M | 1.33M | 0.36M | 0.24M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1.26M | 2.19M | 1.72M | 0.06M | 0.03M |
| Reconciled depreciation | 0.11M | 0.11M | 0.10M | 0.05M | 0.04M |
| Ebit | -0.29118M | 1.06M | 1.27M | -0.27570M | 0.06M |
| Ebitda | -0.18576M | 1.16M | 1.38M | -0.22237M | 0.10M |
| Depreciation and amortization | 0.11M | 0.11M | 0.10M | 0.05M | 0.04M |
| Non operating income net other | - | -0.23395M | 0.15M | - | - |
| Operating income | -0.29118M | 1.06M | 1.27M | -0.27570M | 0.06M |
| Other operating expenses | 11.22M | 12.31M | 10.12M | 0.40M | 0.15M |
| Interest expense | 0.01M | 0.01M | 0.01M | 0.00000M | 0.00000M |
| Tax provision | 0.05M | 0.29M | 0.17M | -0.02924M | 0.03M |
| Interest income | - | - | - | - | - |
| Net interest income | -0.01248M | -0.01297M | -0.01131M | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.05M | 0.29M | 0.17M | -0.02924M | 0.03M |
| Total revenue | 10.93M | 13.36M | 11.39M | 0.13M | 0.21M |
| Total operating expenses | 1.55M | 1.14M | 0.45M | 0.33M | -0.03114M |
| Cost of revenue | 9.67M | 11.17M | 9.67M | 0.07M | 0.18M |
| Total other income expense net | -0.01248M | -0.01297M | -0.01131M | 0.03M | 0.27M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -0.35597M | 0.80M | 1.42M | -0.24647M | 0.03M |
| Net income applicable to common shares | - | 0.75M | 1.09M | -0.24647M | 0.03M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11.40M | 8.74M | 9.57M | 10.12M | 1.23M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.12M | 1.54M | 0.07M | 6.09M | 0.51M |
| Total liab | 1.74M | 2.08M | 2.39M | 3.45M | 0.11M |
| Total stockholder equity | 9.66M | 6.67M | 7.18M | 6.66M | 1.12M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.19M | 0.10M | 0.17M | 0.16M | 0.02M |
| Common stock | 17.19M | 10.93M | 10.78M | 10.78M | 6.48M |
| Capital stock | 17.19M | 10.93M | 10.78M | 10.78M | 6.48M |
| Retained earnings | -1.84428M | 1.16M | 1.51M | 0.76M | -0.33331M |
| Other liab | - | - | 0.03M | 0.00187M | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 5.93M | 2.12M | 2.12M | 2.79M | 0.86M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1.63M | 2.00M | 2.33M | 3.37M | 0.05M |
| Current deferred revenue | - | 0.02M | 0.11M | - | - |
| Net debt | -5.79594M | -2.06209M | -2.04697M | -2.66427M | -0.76964M |
| Short term debt | 0.03M | 0.02M | 0.04M | 0.05M | 0.03M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.13M | 0.06M | 0.08M | 0.12M | 0.09M |
| Other stockholder equity | -6.85617M | -5.01189M | -5.01189M | -5.01189M | -5.01189M |
| Property plant equipment | - | - | 1.63M | 1.79M | 0.34M |
| Total current assets | 8.05M | 6.02M | 7.15M | 7.99M | 0.88M |
| Long term investments | 1.70M | 1.15M | 0.75M | 0.28M | 0.01M |
| Net tangible assets | - | - | 7.18M | 6.66M | 1.12M |
| Short term investments | 3.31M | - | - | - | - |
| Net receivables | 0.98M | 2.93M | 3.44M | 4.02M | 0.02M |
| Long term debt | - | - | - | - | - |
| Inventory | 1.14M | 0.98M | 1.52M | 1.18M | 0.00758M |
| Accounts payable | 1.40M | 1.86M | 2.01M | 3.17M | - |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.67729M | -0.40906M | -0.10026M | 0.13M | -0.01710M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 10.78M | 10.78M | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | 1.51M | 0.76M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | 0.79M | 0.34M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3.35M | 2.72M | 2.42M | 2.13M | 0.35M |
| Capital lease obligations | 0.13M | 0.06M | 0.08M | 0.12M | 0.09M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.45050M | -0.50945M | -0.07857M | -0.07857M | -0.01208M |
| Change to liabilities | - | -1.18053M | -0.52424M | -0.03060M | -0.46360M |
| Total cashflows from investing activities | - | -0.49057M | 1.32M | -0.01282M | -0.05170M |
| Net borrowings | - | -0.00192M | -0.00495M | -0.01784M | 0.00144M |
| Total cash from financing activities | 0.12M | -0.02822M | -0.00495M | -0.18080M | 0.74M |
| Change to operating activities | - | -0.05747M | 0.04M | -0.01101M | -0.01101M |
| Net income | -0.35597M | 0.75M | 1.09M | -0.24647M | 0.03M |
| Change in cash | -0.00505M | -0.66377M | 1.93M | -0.40116M | 0.42M |
| Begin period cash flow | 2.12M | 2.79M | 0.86M | 1.26M | 0.84M |
| End period cash flow | 2.12M | 2.12M | 2.79M | 0.86M | 1.26M |
| Total cash from operating activities | 0.54M | 0.00916M | 0.55M | -0.21727M | -0.27408M |
| Issuance of capital stock | 0.15M | - | - | - | - |
| Depreciation | 0.11M | 0.11M | 0.10M | 0.05M | 0.04M |
| Other cashflows from investing activities | - | 0.02M | 1.82M | 0.00631M | 0.00631M |
| Dividends paid | -0.00000M | -0.02204M | -0.00631M | - | - |
| Change to inventory | 0.54M | -0.34575M | 0.15M | 0.00772M | 0.02M |
| Change to account receivables | 0.54M | 0.58M | 0.41M | 0.00976M | 0.11M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 0.00000M | 0.02M | 0.00631M | -0.16403M | 0.74M |
| Change to netincome | - | 0.00381M | 0.00266M | -0.74538M | -0.74538M |
| Capital expenditures | 0.05M | 0.00316M | 0.42M | 0.01M | 0.04M |
| Change receivables | - | 0.58M | 0.41M | - | - |
| Cash flows other operating | - | 0.07M | 0.52M | - | - |
| Exchange rate changes | - | - | 0.06M | - | - |
| Cash and cash equivalents changes | - | -0.50963M | 1.93M | - | - |
| Change in working capital | 0.83M | -0.86225M | 0.10M | -0.02414M | -0.34114M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -0.03881M | 0.01M | -0.74538M | - | - |
| Free cash flow | 0.49M | 0.00600M | 0.13M | -0.23009M | -0.31370M |
Sector: Basic Materials Industry: Specialty Chemicals
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BGLC BioNexus Gene Lab Corp Common stock |
-0.03 1.01% | 2.95 | - | - | 0.57 | 0.56 | 0.14 | 629.53 |
| LIN Linde plc Ordinary Shares |
-0.08 0.02% | 455.42 | 33.77 | 28.90 | 6.56 | 5.42 | 7.03 | 18.92 |
| AIQUF L'Air Liquide S.A |
0.005 0.0024% | 208.32 | 29.39 | 24.69 | 3.41 | 3.97 | 3.87 | 15.91 |
| AIQUY Air Liquide SA ADR |
- -% | 41.80 | 30.34 | 23.04 | 3.63 | 3.77 | 3.88 | 15.62 |
| SHW Sherwin-Williams Co |
-1.7 0.48% | 352.24 | 33.33 | 27.40 | 3.38 | 20.60 | 3.88 | 21.36 |
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Tower B, Avenue 3, Kuala Lumpur, Malaysia, 59200
| Name | Title | Year Born |
|---|---|---|
| Ms. Wei Li Leong | CFO & Principal Accounting Officer | 1989 |
| Mr. Liong Tai Tan | COO & Exec. Director | 1959 |
| Mr. Sook Keng Yeoh | CEO & Director | 1958 |
| Ms. Yee Meng Wong | Pres & Director | 1985 |
| Dr. Choong-Chin Liew | Co-Founder, Chief Scientist & Scientific Adviser | 1938 |
| Mr. Kwan Wah Chan | Marketing Mang. | NA |
| Mr. Too Kam Tham | Managing Director | NA |
| Mr. Su-Leng Tan | CEO & Director | 1984 |
| Mr. Kwan Wah Chan | Marketing Manager | NA |
| Mr. Su-Leng Tan | CEO, Acting CFO, Secretary & Director | 1983 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...